|
|
Post by peppy on Feb 22, 2023 9:39:51 GMT -5
eight mins in, MNKD is even
5.270.00 (0.00%)
As of 09:38AM EST. Market open.
455,791 shares
Avg. Volume 3,833,026
|
|
|
|
Post by peppy on Feb 22, 2023 8:42:20 GMT -5
Interesting that pre-market is now showing down to $5.00 with lots of trades but only two over 1,000 shares and none of significant size. This appears to be a typical misleading attack that will turn quickly. Today could get quite interesting. and going up. 5.12 -0.15 (-2.85%) Pre-Market: 08:40AM EST Don't get distracted. This dip was a buy opportunity. |
|
|
|
Post by peppy on Feb 22, 2023 8:07:51 GMT -5
the fourth quarter and year ended December 31, 2022. Full year total revenues rose to a record $1.94 billion, as U.S. patients being treated with the company’s treprostinil-based therapies reached an all-time high during the fourth quarter of 2022.
"We’re now focused on continued commercial uptake of Tyvaso and Tyvaso DPI in both PAH and PH-ILD to support our long-term goal of doubling our revenue to a $4 billion run rate by the end of 2025."
"We are tremendously proud of reaching our goal of doubling the number of patients on Tyvaso therapy since the Tyvaso PH-ILD approval in early 2021," said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. "We’re now focused on continued commercial uptake of Tyvaso and Tyvaso DPI in both PAH and PH-ILD to support our long-term goal of doubling our revenue to a $4 billion run rate by the end of 2025."
|
|
|
|
Post by peppy on Feb 22, 2023 7:50:11 GMT -5
|
|
|
|
Post by peppy on Feb 21, 2023 16:12:48 GMT -5
MNKD Nasdaq real time volume, 4,149,278 shares. MNKD Nasdaq summary volume, 4,028,532 Avg. Volume 3,833,246 $5.27-0.36 (-6.39%) MNKD share price did take out Friday's low, however MNKD share price did not take out last weeks work. I am going to post weekly charts. Today, Tuesday the first trading day of the week, so the last candle on the chart is todays movement. MNKD weekly. schrts.co/wJpeDFzk$COMPQ weekly, schrts.co/MjwQNHCbThe SPX took out three weeks of price work..... schrts.co/sWccyxzpUTHR reports tomorrow......https://schrts.co/vWVFveBh |
|
|
|
Post by peppy on Feb 21, 2023 15:01:42 GMT -5
Inspire sleep .com the type of add discussed on this board recently. I saw it on CNBC .. effective/ check it out … entices you to go to their website : Turns out surgeons can implant inspire into your chest and inspire is capable of monitoring breathing, and putting out a charge of sorts to move the back of the tongue forward with every breath. www.inspiresleep.com/faq/#how-it-worksI get the feeling it requires a pre-authorization letter "Your doctor will create an individualized care plan, which may include a sleep study or an airway exam. For your initial Inspire consultation, you will need to: Bring your most recent sleep study and CPAP compliance report. Your doctor will determine if an updated sleep study is needed. Be ready to talk about your struggles using CPAP and any sleep-related topics including prescription sleep medication, insomnia, and sleep anxiety. Write down any questions you have for the doctor. After the initial consultation, your doctor will provide next steps including an airway exam. An airway exam is an approximately 20-minute non-surgical procedure. The doctor will look inside your airway with a small camera to confirm that Inspire is right for you. Most insurance providers cover Inspire. An Inspire-trained doctor can discuss insurance coverage requirements during an initial consultation." |
|
|
|
Post by peppy on Feb 21, 2023 12:47:11 GMT -5
MNKD volume at the half day of trade, real time, 1,451,047 shares. summary, 1,452,668 Avg. Volume 3,833,246 $5.38. -0.26 (-4.53%) An inside day for MNKD, after making a new 52 week high on Friday. UTHR running positive on the day reporting tomorrow morning. schrts.co/EvjiQsdQ |
|
|
|
Post by peppy on Feb 21, 2023 5:47:14 GMT -5
Is that more important than obfuscation (for competitive reasons) at this point in time? Serious question. I would expect their drug lines to broadly continue dropping; Remodulin is losing sales to the Liquidia generic sold by Sandoz, Adcira has been dropping ever since it came off patent, and Orenitram (oral treprostinil) is going nowhere. The only growth area is Tyvaso so they need to push that or risk falling back to the $100 support line. But just remember that I am famously bad at picking stocks... "they need to push that or risk falling back to the $100 support line." Nope. UTHR Monthly chart. schrts.co/iTcrzBcGYou are famously bad at reading charts as well then? By the way some Pharma companies have been the ones going up during the $COMPQ 16,000 to !0,000. MRK monthly schrts.co/eIzmCqQBREGN. schrts.co/FKnVCNIzAMGN. schrts.co/UISxMpxQThe dow playing musical chairs. To make up for BA, MSFT, NIKE, etc etc. |
|
|
|
Post by peppy on Feb 20, 2023 12:54:52 GMT -5
I thought it was also quite interesting Martin Shkreli published on his sub stack for his followers to sell Liquidia. Appears Squirrelli may not be so confident in their near term future, eh? I bet Shkreli shorted LQDA. However, I will never know. Just motives and all. |
|
|
|
Post by peppy on Feb 18, 2023 23:45:15 GMT -5
Any bets on MNKD price action on Feb 22nd? We have to assume UTHR will present great results, and therefore the pessimistic side of me says the shorts will pour it on to keep a lid on and avoid a breakout. It will be a day to watch naked shorting. Nobody needs to naked short, there is a ton of stock available to borrow so they can simply short if they want. That said, my suspicion is that it all depends on the UTHR call. If DPI has knocked it out of the ball park I expect MNKD to rise smartly. If DPI is in line with projection then maybe a small bump as that's already priced in. Bingo |
|
|
|
Post by peppy on Feb 18, 2023 14:51:31 GMT -5
Please do ask ChatGPT and please report back. That should be fun.
|
|
|
|
Post by peppy on Feb 18, 2023 13:06:28 GMT -5
I heartily agree with this. There is no way I can see Novo Nordisk is the partner since in addition to the Ozempic (the largest selling GLP-1 and 6th largest prescription drug by Rx dollars last I looked), but they also make Novolog and Fiasp which which pretty much split the RAA market with Lilly. I cannot see them encouraging the use of Afrezza. Maybe its time to load Novolog on Technosphere and NVO starts pitching Inhaled Novolog. Novolog would need to be tested and go through approval. That was an awaking when Heard, Afrezza is approved to be made with the 1 regular insulin that was used upon approval. amphastar.com/facilities.htmlYou knew that. |
|
|
|
Post by peppy on Feb 18, 2023 11:44:45 GMT -5
The chart pattern. If price makes it to $5.90- $5.92 the triangle comes into play. Less than 30 cents away. schrts.co/hJWhqwBcThis particular triangle set up. NOT an ascending triangle..... NOT a continuation pattern This triangle a six year bottoming change of trend triangle.... this one when it pops instead of making new highs, this triangle price will walk up the wedge. There has been discussion about shorts, I think any shorts that haven't covered will cover @ $6.00. Monday is presidents day, the market is closed. Charts do not make this type of up trending pattern, STRONG up trending pattern in an over all down trend with out the market participants taking it up. The market has taken this up in a down trend for reason, now the pop. I am a simpleton. plus, the wedge break target, the inverted target, the triangle target, one target leading into the other.... |
|
|
|
Post by peppy on Feb 17, 2023 19:54:08 GMT -5
The way MNKD share price is behaving, and the information we have regarding potential revenue and the chart pattern, MNKD could gap up. I would bet on the gap over the sell off. I hope you’re right but we’ve been disappointed before. None of us has a crystal ball.We have Bloomberg.  |
|
|
|
Post by peppy on Feb 17, 2023 19:14:39 GMT -5
I’m nervous that the stock price is running up into earnings then sell off like it has in the past. If I sell short term coved calls, I could catch the dip if there is one. With my luck there will be no dip after earnings. Does anyone else sell short term covered calls around earnings release? The way MNKD share price is behaving, and the information we have regarding potential revenue and the chart pattern, MNKD could gap up. I would bet on the gap over the sell off. |
|
